Amarin Corporation plc · NASDAQ:AMRN
Amarin — Amarin Corp Plc\uk — Investor Presentation (May 2007)
21 slides from Amarin's investor presentation, May 17, 2007
Slide 1: www.amarincorp.com
1 www.amarincorp.com
Slide 2: Safe Harbour
Safe Harbour DISCLOSURE NOTICE: The information contained in this document is as of May, 2007. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking stat
Slide 3: Corporate Focus
Corporate Focus A Neuroscience Company Focused on Researching, Developing and Commercializing Novel Drugs for the Treatment of Central Nervous System Disorders
Slide 4: Investment Highlights
Investment Highlights • Focused growth strategy managing risk ü Improved Outcome focus ü Selective internal development & in-licensing of New Chemical Entities ü Out-license outside U.S. & Outside Neuroscience Ÿ Robust Neuroscience Pipeline – 4 Key Programs ü Parkinson’s disease - oral apomorphine ü
Slide 5: Core Pipeline with Large Market Potential
Miraxion for HD Miraxion for PD Nasal lorazepam for ES Apomorphine for PD On Hold Phase II YE 2007 Phase II 2008 Phase I YE 2007 Levadopa Transport AMR-109 Phase I/II YE 2007 Under review Core Pipeline with Large Market Potential Pre-Clinical Phase I Phase II Phase III
Slide 6: Miraxion Phase III Results
Miraxion Phase III Results • No statistical significance or clinically meaningful difference between Miraxion and placebo • Largest therapeutic study in Huntington’s disease ü Total of 606 patients in N.American & European trials combined • Well Designed & conducted trials ü Collaboration with Hunti
Slide 7: Miraxion for HD – Phase III Trial Design
Miraxion for HD – Phase III Trial Design Powering: pts; 90% Clinical Centers Patient Entry Criteria CAG ≤ : Less severe Detect TMS-4 change of 3.2 in US and 3.5 in EU centers, 6 month trial, month extension Regulatory Agencies Expert involvement Current Phase III Trial
Slide 8: Strategic Product Development
Strategic Product Development • Balance risk by developing Improved Outcome products and NCE’s • Lower risk & lower cost development of Improved Outcome versions of existing drugs • Address unmet medical needs via reformulation or route of administration • Internal & external (in-licensing) developm
Slide 9: Key Development Programs
4 Key Development Programs 1. Oral formulation of apomorphine for “frozen” periods in advanced Parkinson’s disease - Advance into Phase II late this year or early next year 2. Nasal formulation of lorazepam for epilepsy seizures - Targeted to initiate Phase II in 2008 3. Combinatorial lipid formulat
Slide 10: Apomorphine for Parkinson’s Disease
Apomorphine for Parkinson’s Disease Market Size $100M+ 700,000 advanced patients experience frequent "off" episodes > 2 million diagnosed with Parkinson's • 30% of patients have advanced Parkinson’s disease • Characterized by frequent “off” periods of semi-paralysis • Current injectable apomorphine
Slide 11: Nasal Lorazepam for Emergency Seizures
nasal lorazepam formulation Nasal Lorazepam for Emergency Seizures $300M Product Opportunity 150,000 episodes of Status Epilepticus p.a. 400,000 Acute Repetitive Seizure patients • Unmet medical need • 40,000 deaths in US per year • Emergency seizures • Rectal diazepam gel only out-patient option –
Slide 12: Targeted Transport of Levodopa for Parkinson’s
Targeted Transport of Levodopa for Parkinson’s Approx 70% of Parkinson’s patients prescribed C-L Dopa Approx 1.5 million Parkinson’s patients in U.S • Levodopa is current “Gold Standard” for treatment of Parkinson’s disease • Poorly & erratically absorbed plus extensively broken down in periphery •
Slide 13: AMR-109 for Memory & Cognition
AMR-109 for Memory & Cognition • Extensive scientific evidence of fatty acid role in brain function • Pre-clinical proof of concept on role of long chain fatty acids in memory & cognition • Impact on long term potentiation • CMC & toxicology near completion • Proof-of-concept study to commence by en
Slide 14: Combinatorial Lipid Program
Combinatorial Lipid Program • Proprietary technology platform • Chemically conjugating bioactive lipids with other lipids or existing drugs • Results in novel single chemical entities (NCE’s) with predictable properties offering clinically relevant advantages - Improved blood brain barrier penetrati
Slide 15: Combinatorial Lipid Advantage
Combinatorial Lipid Advantage • Potential vast library of compounds • CNS, Cardio, GI, Oncology and more • Patent protected plus Know-how • New compounds and exciting enhancements of existing compounds ü entirely new therapeutic actions ü improvements in existing therapeutic actions ü improved oral
Slide 16: Out-licensing /Partnering Opportunities
Out-licensing /Partnering Opportunities • European/ROW rights to: - Apomorphine for PD - Combinatorial Levadopa product - Nasal lorazepam for emergency seizures in epilepsy - AMR-109 for Memory & cognition • Combinatorial Lipid Program (transport technology) outside neurology • Miraxion for depressi
Slide 17: Partner logos
CardinalHealth {el Cephalon Phized SE SkyePharma pic th Novartis élan THE FUTURE IN wo We
Slide 18: Capitalization and Financials
Warrants Options Common Shares Debt Cash position 10.0m 9.0m 90.7m None $29 m 31/03/07 Capitalization Financials Directors and officers own 28% of Amarin
Slide 19: Newsflow - Twelve Month Milestones
Newsflow - Twelve Month Milestones • Complete formulation optimization for Apomorphine PD program & initiate Phase II trials • Complete pre-clinical pharmacokinetic studies of nasal lorazepam & initiate clinical program • Initiate Phase I study of levadopa transport technology • Initiate human proof
Slide 20: Investment Highlights
Focused strategy managing risk Seasoned CNS Management Team Large Market Opportunities in CNS Large Market Opportunities in CNS Diseases Strong Financials: $29 million in cash - No Debt Robust Pipeline in CNS Diseases Investment Highlights
Slide 21: www.amarincorp.com
21 www.amarincorp.com
Amarin Corp Plc\uk — Investor Presentation (May 2007) on 6ix